Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN A ROSENBERG

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1811150725
CMS profile
37047
Location
GURNEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$151,950.45

325 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 7 of 7; records 301–325 of 325 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN A ROSENBERG

NPI 1811150725 · CMS profile ID 37047

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GURNEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 7 of 7; records 301–325 of 325 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=7#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN A ROSENBERG, NPI 1811150725, CMS profile ID 37047. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 7; records 301–325 of 325 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JONATHAN A ROSENBERG, NPI 1811150725, CMS profile ID 37047. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 7; records 301–325 of 325 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JONATHAN A ROSENBERG, NPI 1811150725, CMS profile ID 37047, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 7; records 301–325 of 325 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1811150725?year=2019&recipient=provider&page=7#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

325 matching records · $151,950.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 325 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 301–325 of 325.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $3,850.0002/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043697 CMS
Allergan Inc. $20.2202/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043699 CMS
Allergan Inc. $130.0002/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043705 CMS
Allergan Inc. $20.9702/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043709 CMS
Allergan Inc. $24.7102/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043713 CMS
Allergan Inc. $333.3902/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043719 CMS
Boston Scientific Corporation $17.0302/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662947749 CMS
PFIZER INC. $14.9002/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671870195 CMS
Takeda Pharmaceuticals U.S.A., Inc. $5.6002/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682052419 CMS
Allergan Inc. $21.6801/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043669 CMS
Boston Scientific Corporation $115.8901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662947763 CMS
Horizon Therapeutics plc $2,080.0001/30/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691483509 CMS
UCB, Inc. $20.9501/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688252399 CMS
Allergan Inc. $2,200.0001/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043639 CMS
Allergan Inc. $5.0001/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043647 CMS
Allergan Inc. $24.7101/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043655 CMS
Allergan Inc. $5.0001/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043657 CMS
Allergan Inc. $3,300.0001/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671043665 CMS
Janssen Biotech, Inc. $19.5901/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658678643 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.7701/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684911685 CMS
AbbVie, Inc. $21.4101/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647901265 CMS
Dova Pharmaceuticals $19.6801/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705233050 CMS
Gilead Sciences, Inc. $17.2901/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681594373 CMS
Daiichi Sankyo Inc. $23.5801/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695280743 CMS
UCB, Inc. $16.4401/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688244855 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $151,950.45 325
PY2020 $59,956.16 87
PY2021 $90,781.81 164
PY2022 $120,586.80 230
PY2023 $213,246.44 377
PY2024 $242,690.33 449
PY2025 $140,200.01 315

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $96.39 1
PY2025 Principal investigator $708,726.43 147
PY2024 Principal investigator $664,829.42 149
PY2023 Principal investigator $465,280.81 125
PY2022 Principal investigator $137,067.90 52
PY2021 Principal investigator $21,800.00 2
PY2020 Principal investigator $20,268.64 31
PY2019 Recipient $1,932.14 6
PY2019 Principal investigator $87,072.39 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

148 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,850.00 12/31/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202535287
Principal investigator 1 ABBVIE INC. $14,149.80 12/30/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202532206
Principal investigator 1 ABBVIE INC. $91,714.00 12/30/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202532208
Principal investigator 1 Genentech, Inc. $14,308.00 12/19/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663503
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786307
Principal investigator 1 Boehringer Ingelheim International GmbH $14.43 12/17/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786309
Principal investigator 1 Boehringer Ingelheim International GmbH $14.43 12/17/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786311
Principal investigator 1 Boehringer Ingelheim International GmbH $14.43 12/17/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786313
Principal investigator 1 Boehringer Ingelheim International GmbH $14.43 12/17/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786315
Principal investigator 1 Genentech, Inc. $4,725.00 12/11/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663491
Principal investigator 1 Eli Lilly and Company $324.14 12/08/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187893116
Principal investigator 1 ABBVIE INC. $3,081.40 12/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202528222
Principal investigator 1 Phathom Pharmaceuticals, Inc. $3,000.00 12/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSUL
EoE-201 No dispute reported 06/30/2026 1224868881
Principal investigator 1 Phathom Pharmaceuticals, Inc. $12,000.00 12/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSUL
EoE-201 No dispute reported 06/30/2026 1224869010
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,940.00 11/21/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Southlake
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1235993305
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 11/13/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786285
Principal investigator 1 Boehringer Ingelheim International GmbH $2,195.20 11/13/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786287
Principal investigator 1 Boehringer Ingelheim International GmbH $2,195.20 11/13/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786289
Principal investigator 1 Boehringer Ingelheim International GmbH $11,410.00 11/13/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786291
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786293
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786295
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786297
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786299
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786301
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786303
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 10/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786305
Principal investigator 1 ABBVIE INC. $2,696.40 10/09/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202514081
Principal investigator 1 PFIZER INC. $680.00 10/09/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants PLLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228748288
Principal investigator 1 Genentech, Inc. $392.00 09/24/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663336
Principal investigator 1 Genentech, Inc. $867.00 09/24/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663346
Principal investigator 1 Genentech, Inc. $3,390.00 09/18/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663297
Principal investigator 1 ABBVIE INC. $4,554.20 09/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202508782
Principal investigator 1 Ferring Pharmaceuticals AS $1,908.20 09/04/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060937
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 08/26/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786283
Principal investigator 1 Genentech, Inc. $1,695.00 08/21/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663289
Recipient Eli Lilly and Company $96.39 08/19/2025 Covered Recipient Physician A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1187871051
Principal investigator 1 GENZYME CORPORATION $2,085.70 08/18/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120714
Principal investigator 1 Ferring Pharmaceuticals AS $9,341.00 08/14/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060858
Principal investigator 1 ABBVIE INC. $8,334.20 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202502268
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283819
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283821
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283835
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283839
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 08/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223283841
Principal investigator 1 Boehringer Ingelheim International GmbH $4,145.40 07/30/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786269
Principal investigator 1 Boehringer Ingelheim International GmbH $3,588.20 07/30/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786271
Principal investigator 1 Boehringer Ingelheim International GmbH $3,441.20 07/30/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786273
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786281
Principal investigator 1 Ferring Pharmaceuticals AS $628.29 07/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060806
Principal investigator 1 Genentech, Inc. $160.00 07/22/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663293
Principal investigator 1 GENZYME CORPORATION $1,050.00 07/21/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120691
Principal investigator 1 PFIZER INC. $6,494.00 07/14/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants PLLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228724690
Principal investigator 1 PFIZER INC. $3,366.00 07/11/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants PLLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228743657
Principal investigator 1 ABBVIE INC. $10,007.20 07/02/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202494753
Principal investigator 1 GENZYME CORPORATION $194.05 07/02/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120677
Principal investigator 1 GENZYME CORPORATION $45,381.00 07/02/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120687
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786275
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 06/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786257
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 06/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786259
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 06/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786261
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 06/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786263
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 06/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786265
Principal investigator 1 Boehringer Ingelheim International GmbH $9.62 06/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786267
Principal investigator 1 Ferring Pharmaceuticals AS $37,849.00 06/24/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060680
Principal investigator 1 ABBVIE INC. $5,392.80 06/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202491371
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 06/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223280820
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786279
Principal investigator 1 Genentech, Inc. $2,922.00 05/27/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663234
Principal investigator 1 ABBVIE INC. $21,500.00 05/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202485153
Principal investigator 1 Ferring Pharmaceuticals AS $533.40 05/15/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060312
Principal investigator 1 Boehringer Ingelheim International GmbH $1.89 05/08/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786237
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 05/08/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786239
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/08/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786241
Principal investigator 1 Boehringer Ingelheim International GmbH $147.49 05/08/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786243
Principal investigator 1 Genentech, Inc. $3,447.00 05/08/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663134
Principal investigator 1 ABBVIE INC. $6,463.80 05/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202483769
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786245
Principal investigator 1 Genentech, Inc. $976.00 04/30/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663279
Principal investigator 1 Boehringer Ingelheim International GmbH $20.65 04/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786227
Principal investigator 1 Boehringer Ingelheim International GmbH $25.20 04/24/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786229
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 04/23/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786247
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 04/23/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786249
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 04/23/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786251
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 04/23/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786253
Principal investigator 1 Boehringer Ingelheim International GmbH $19.24 04/23/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786255
Principal investigator 1 PFIZER INC. $2,542.00 04/23/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228790266
Principal investigator 1 PFIZER INC. $1,906.00 04/23/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228790512
Principal investigator 1 PFIZER INC. $294.00 04/23/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228791509
Principal investigator 1 PFIZER INC. $1,358.00 04/23/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228791512
Principal investigator 1 PFIZER INC. $810.00 04/23/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228791763
Principal investigator 1 PFIZER INC. $74.00 04/23/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE No dispute reported 06/30/2026 1228792159
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 04/09/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223277648
Principal investigator 1 Genentech, Inc. $3,188.00 04/08/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663100
Principal investigator 1 Boehringer Ingelheim International GmbH $225.00 04/07/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786225
Principal investigator 1 Boehringer Ingelheim International GmbH $161.00 04/07/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786231
Principal investigator 1 ABBVIE INC. $2,871.40 04/03/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202471173
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786233
Principal investigator 1 Genentech, Inc. $18,040.00 04/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663148
Principal investigator 1 Genentech, Inc. $3,400.00 04/01/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211663201
Principal investigator 1 Genentech, Inc. $976.00 03/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663048
Principal investigator 1 Genentech, Inc. $7,695.00 03/25/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211663074
Principal investigator 1 Genentech, Inc. $2,928.00 03/21/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663054
Principal investigator 1 PFIZER INC. $680.00 03/21/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants PLLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228786776
Principal investigator 1 PFIZER INC. $6,132.50 03/19/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775548
Principal investigator 1 Ferring Pharmaceuticals AS $74.20 03/13/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060264
Principal investigator 1 Ferring Pharmaceuticals AS $1,257.20 03/13/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection No dispute reported 06/30/2026 1242060269
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,554.95 03/13/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044704
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,100.00 03/13/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 03/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223276285
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 03/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223276287
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $668.25 03/12/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC
A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL No dispute reported 06/30/2026 1223276289
Principal investigator 1 ABBVIE INC. $5,952.80 03/07/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202459499
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786193
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786195
Principal investigator 1 Boehringer Ingelheim International GmbH $1,078.00 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786197
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786199
Principal investigator 1 Boehringer Ingelheim International GmbH $16,500.00 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786201
Principal investigator 1 Boehringer Ingelheim International GmbH $3,617.86 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786203
Principal investigator 1 Boehringer Ingelheim International GmbH $210.34 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786205
Principal investigator 1 Boehringer Ingelheim International GmbH $36.21 03/06/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786207
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786235
Principal investigator 1 Genentech, Inc. $976.00 02/28/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLCD B A GI ALLIANCE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663555
Principal investigator 1 Boehringer Ingelheim International GmbH $36.21 02/26/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786191
Principal investigator 1 Boehringer Ingelheim International GmbH $128.26 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786209
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786211
Principal investigator 1 Boehringer Ingelheim International GmbH $1,022.00 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786213
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786215
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786217
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786219
Principal investigator 1 Boehringer Ingelheim International GmbH $24.05 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786221
Principal investigator 1 Boehringer Ingelheim International GmbH $146.55 02/25/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786223
Principal investigator 1 GENZYME CORPORATION $525.00 02/24/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120626
Principal investigator 1 GENZYME CORPORATION $24,024.00 02/24/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120638
Principal investigator 1 GENZYME CORPORATION $9,704.80 02/24/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120642
Principal investigator 1 GENZYME CORPORATION $1,467.35 02/18/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120653
Principal investigator 1 ABBVIE INC. $14,460.60 02/06/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONS PLLC
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202449442
Principal investigator 1 GENZYME CORPORATION $55,669.00 02/04/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Pllc Gi Alliance
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE) No dispute reported 06/30/2026 1226120646
Principal investigator 1 PFIZER INC. $1,309.00 02/03/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants PLLC
AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1228775556
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786277
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14.75 01/27/2025 Non-covered Recipient Entity
GI Alliance Of Illinois
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235997105
Principal investigator 1 Genentech, Inc. $6,832.00 01/24/2025 Non-covered Recipient Entity
TEXAS DIGESTIVE DISEASE CONSULTANTS PLLCD B A GI ALLIANCE
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211663518
Principal investigator 1 Celgene Corporation $35,614.25 01/17/2025 Non-covered Recipient Entity
GI Alliance Department Of Clinical Research And Education
A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cendakimab No dispute reported 06/30/2026 1222306889
Principal investigator 1 Celgene Corporation $22,656.40 01/13/2025 Non-covered Recipient Entity
GI Alliance Department Of Clinical Research And Education
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. No dispute reported 06/30/2026 1222307009
Principal investigator 1 Bausch Health US, LLC $448.00 01/10/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846354
Principal investigator 1 Bausch Health US, LLC $357.00 01/10/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224846380
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,950.00 01/10/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants Southlake
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235993303
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,277.35 01/07/2025 Non-covered Recipient Entity
Texas Digestive Disease Consultants, PLLC
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) No dispute reported 06/30/2026 1244044702
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
GI Alliance Of Illinois-Gurnee
Phase IIa, single arm exploratory clinical trial to evaluate safety, tolerability pharmacokinetics, pharmacodynamics, and clinical effect, of 12-week induction treatment with BI 3032950 in patients with moderate to severe ulcerative colitis No dispute reported 06/30/2026 1220786189

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $19,997.26 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $19,997.26 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $1,256.05 1
PY2021 Amount invested $993.05 1
PY2021 Value of interest $1,241.66 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $19,997.26 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124820162
PY2023 GastroGPO, LLC $0.00 $19,997.26 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050730571
PY2022 GastroGPO, LLC $0.00 $1,256.05 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 955001069
PY2021 GastroGPO, LLC $993.05 $1,241.66 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854914347